Sheaff Brock Investment Advisors LLC Sells 33 Shares of Humana Inc. (NYSE:HUM)

Sheaff Brock Investment Advisors LLC decreased its position in Humana Inc. (NYSE:HUM) by 1.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,691 shares of the insurance provider’s stock after selling 33 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Humana were worth $586,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of HUM. Barlow Wealth Partners Inc. purchased a new stake in shares of Humana in the 4th quarter valued at $1,977,000. Auxano Advisors LLC bought a new stake in shares of Humana in the 4th quarter valued at about $540,000. Intech Investment Management LLC grew its position in Humana by 46.2% during the 4th quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock worth $19,359,000 after acquiring an additional 13,356 shares during the last quarter. AdvisorShares Investments LLC purchased a new position in Humana in the 4th quarter worth approximately $421,000. Finally, Sei Investments Co. lifted its position in Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock valued at $21,462,000 after purchasing an additional 264 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

NYSE:HUM traded up $6.23 on Friday, hitting $392.63. The stock had a trading volume of 875,957 shares, compared to its average volume of 1,736,161. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54. The stock has a market cap of $47.31 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 2.23 and a beta of 0.51. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The business’s 50-day simple moving average is $364.93 and its two-hundred day simple moving average is $347.13.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter last year, the firm posted $9.38 earnings per share. The firm’s revenue was up 10.7% compared to the same quarter last year. As a group, research analysts predict that Humana Inc. will post 16.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. TD Cowen lifted their target price on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday. Bank of America increased their target price on shares of Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a report on Monday, May 20th. Wells Fargo & Company decreased their price objective on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Piper Sandler assumed coverage on shares of Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price target on the stock. Finally, Jefferies Financial Group cut their target price on Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research note on Monday, April 22nd. Fourteen analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $402.60.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.